CLOPAM® · For mRNA & vaccine developers
Your vaccine.Into the skin.Precisely.
- Intradermal dose authorized to stretch a vaccine supply up to five-fold
- 1/5Intradermal dose authorized to stretch a vaccine supply up to five-fold
- Infants seroconverted to measles with a microneedle patch
- 93%Infants seroconverted to measles with a microneedle patch
- Needles, sharps or trained injectors
- 0Needles, sharps or trained injectors
01 — The breakthroughs
mRNA has changed what a vaccine can do.
Personalized cancer vaccines
49%
lower risk of recurrence or death at five years when an individualized mRNA neoantigen therapy was added to a checkpoint inhibitor in resected high-risk melanoma (randomized phase IIb).
T cells that last
7.7 yrs
average estimated lifespan of the CD8 T-cell clones an individualized mRNA vaccine induced in pancreatic cancer; responders stayed recurrence-free far longer (phase 1).
Doses keep shrinking
5 µg
per dose for the first self-amplifying mRNA vaccine authorized in the EU (2025) — a fraction of first-generation mRNA doses. Every microgram saved makes room for a smaller, simpler format.
02 — Why the skin
The skin is the immune system's front door.
Dense with immune sentinels
The epidermis and upper dermis are packed with Langerhans cells and dermal dendritic cells that capture antigen and carry it to the lymph nodes. Muscle has far fewer. Put the dose in the skin and less of it can do the same work.
Kim YC, Park JH, Prausnitz MR. Adv Drug Deliv Rev 2012;64:1547–68
5×
more doses from the same supply: regulators authorized a one-fifth intradermal dose of an mpox vaccine during the 2022 outbreak.
86% vs 68%
type-2 polio seroconversion with two one-fifth intradermal doses, against one full intramuscular dose, in 799 infants.
20 µg
intradermal mRNA booster gave robust antibody responses with fewer systemic side effects than the 50 µg intramuscular booster.
T cells
held up in older adults: a one-fifth intradermal mRNA booster gave comparable or higher T-cell responses than intramuscular, with fewer systemic side effects.
Up to 6×
dose-sparing recorded for influenza, polio and SARS-CoV-2 antigens delivered by microneedle patch.
Dose-sparing
Stretch scarce or costly antigen and mRNA in an outbreak or a launch.
T-cell responses
Dendritic cells in the skin prime the T cells cancer and viral vaccines depend on.
Gentler on the body
Smaller doses with fewer systemic side effects in intradermal studies.
03 — Patches already work
Microneedle patches already vaccinate people.
01
Influenza, adults
≈ IM
A dissolvable microneedle patch matched intramuscular antibody titres for all three strains — including when people applied it themselves. Well tolerated.
02
Measles–rubella, infants
93% · 100%
measles and rubella seroconversion in 9–10-month-old infants with a patch, against 90% and 100% by injection. No related severe or serious adverse events.
03
mRNA in a patch
6 months
mRNA-lipid nanoparticle patches stayed shelf-stable for at least six months at room temperature (model mRNA); in mice, responses matched intramuscular injection. Preclinical.
Not every patch delivers
A needle-free nanoporous patch given an mRNA booster raised no antibody or T-cell response at all. The field's own reviews name sterility assurance, dose uniformity and nucleic-acid integrity as the hurdles left.
Prins MLM et al. Virus Res 2023;334:199175 Nguyen HX et al. Pharmaceutics 2026;18:1022
04 — Why CLOPAM
Built for exactly those hurdles.
Aseptic, needle by needle
Each patch stays sealed in its own mold until use — sterility assurance built into the format, not added after it.
Dose where immunity starts
Patented aero-pressure drying concentrates the antigen or mRNA in the needle tips, which dissolve in the epidermis and dermis.
A dose you can count on
A fixed dose per patch and a pressure-activated applicator for consistent, uniform application, confirmed by a click.
Dry and sealed
A solid, dissolving matrix kept from moisture in hermetic packaging — a route toward a lighter cold chain.
Self-applied, no sharps
No trained injector and nothing sharp to dispose of: built for mass campaigns and outbreak response.
No needle to fear
A painless patch can win over people who put vaccines off.
Already in vaccines
A CLOPAM influenza vaccine is in preclinical development.
Made aseptically at scale
The world's first fully aseptic microneedle patch plant runs in Hyangnam, with a large-scale commercial plant to follow.
Put your vaccine where immunity starts.
Send us your antigen or mRNA-LNP under an MTA. We'll come back with patch feasibility data — loading, stability and delivery into the skin.
Results cited on this page come from published studies of other vaccines and devices, not from CLOPAM. CLOPAM's influenza vaccine is in preclinical development; performance with any antigen or mRNA is confirmed in development.
